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SUMMARY
This study describes the role of parasite clearance time induced by benznidazole, fexinidazole and posaconazole treatments
upon mice infection with a benznidazole-resistant Trypanosoma cruzi strain in the pathological outcomes. Trypanosoma
cruzi-infected mice were treated with diﬀerent drugs and parasite clearance time was detected by blood and tissue qPCR, to
determine the dynamic relationship between the eﬃcacy of the treatments and the intensity of heart lesion/serum
inﬂammatory mediators. Our results indicate that anti-T. cruzi treatments were able to reduce parasite replication and
consequently induce immunomodulatory eﬀects, where the degree of the immunopathology prevention was related to the
time of parasite clearance induced by diﬀerent treatments. Nevertheless, in benznidazole and posaconazole treatments,
parasite rebounding was detected with parasitism reaching levels similar to infected and non-treated mice; the time for
parasitic rebound being earlier among benznidazole-treated mice. In parallel, an increase of cardiac lesions and plasma
chemokine levels was also detected andwasmore accentuated in benznidazole-treated animals. Interestingly, in the presence
of parasitological cure (fexinidazole treatment), basal levels of these inﬂammatory mediators were evidenced as well as an
absence of cardiac inﬂammation or ﬁbrosis. Overall, our data indicate that all treatments have positive eﬀects on the clinical
evolution of T. cruzi infection, with success in preventing cardiac alterations being drug-dependent.
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INTRODUCTION
Chemotherapy for Chagas disease remains unsatis-
factory in terms of both toxicities and lack of
eﬀectiveness. There is a growing consensus that the
persistence of the parasite, together with the imbal-
ance of host immune response, leads to a sustained
inﬂammatory response that underlies the character-
istic lesions of the infection. Machado et al. (2008)
demonstrated that cardiomyocytes are a potential
source of cytokines, chemokines and nitric oxide
(NO) in vivo. In mice infection, these factors may
contribute to the recruitment, placement and mi-
gration of inﬂammatory cells in heart tissue, leading
to the persistence of myocarditis. Chemokines such
as CCL2 have emerged as critical in infections
and autoimmune myocarditis (Paiva et al. 2009).
Specially in Trypanosoma cruzi infection, this
chemokine is intensely produced in the heart of
infected mice and its involvement in parasitic uptake
and destruction by macrophage has been demon-
strated (Aliberti et al. 1999; Machado et al. 2000;
Paiva et al. 2009). Another chemokine observed in
macrophages and cardiomyocytes infected with
T. cruzi is CCL5, and in several studies the role of
this chemokine in attracting leucocytes and its
probable involvement in controlling the growth of
T. cruzi and NO production have been described
(Sallusto et al. 1998; Aliberti et al. 1999; Cook et al.
1999; Machado et al. 2000; Talvani et al. 2000).
These ﬁndings suggest that eradication of the parasite
may be a prerequisite to contain the development of
Chagas disease, preventing its irreversible long-term
consequences. Thus, the identiﬁcation of new drugs
and assessing the impact of antiparasitic treatment on
the prevention of morbidity for infected individuals
remain as major challenges in health promotion and
disease control (Urbina, 2010).
Current drugs for Chagas disease, such as
nifurtimox and benznidazole, require long-term
* Corresponding author: Laboratório de Doença de
Chagas, sala 39, Instituto de Ciências Biológicas, ICEB
II, Universidade Federal de Ouro Preto, Ouro Preto, MG,
35400-000, Brazil. E-mail: mtbahia@nupeb.ufop.br
1628
Parasitology (2014), 141, 1628–1637. © Cambridge University Press 2014
doi:10.1017/S0031182014000882
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0031182014000882
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 11 Jul 2017 at 09:57:22, subject to the Cambridge Core terms of use, available at
administration and often show eﬃcacy problems,
including insuﬃcient activity in established, chronic
forms of the disease (Cançado, 2000). However,
nitroheterocyclics are a well-known class of pharma-
cologically active compounds that deserve special
attention for the treatment of infectious diseases. The
antimicrobial toxicity of nitroimidazoles is depen-
dent on reduction by nitroreductases of the nitro
group that generate cytotoxic species that cause
damage to DNA, lipids and proteins (Do Campo
and Moreno, 1986; Hall and Wilkinson, 2011).
Fexinidazole, a 2-substituted 5-nitroimidazole, was
originally synthesized by Hoechst in the 1970s, and
has recently been identiﬁed as a promising new drug
candidate for treatment of African trypanosomiasis
(Torreele et al. 2010). Fexinidazole has previously
been shown to act in vivo against T. cruzi (Raether
and Seidenath, 1983). These results were conﬁrmed
by Bahia et al. (2012) where the authors demo-
nstrated that treating mice with fexinidazole cured
acute and chronic experimentalT. cruzi infection and
the eﬃcacy of this drug was equivalent in benznida-
zole susceptible and resistant parasite stocks.
New treatment options also include inhibitors of
the sterol biosynthesis pathway, in particular C14-α-
demethylase inhibitors such as posaconazole and
ravuconazole that represent promising target drugs
(Molina et al. 2000; Diniz et al. 2010, 2013). It has
been argued that the in vivo antiparasitic activities of
these compounds are a result of a combination of their
potent and selective intrinsic anti-T. cruzi activity
and their pharmacokinetic properties, such as long
terminal half-life and large volumes of distribution
(Urbina, 2010).
Natural resistance of some T. cruzi strains to
nitroderivative compoundsmight explain therapeutic
failure in Chagas disease. However, drug-induced
reduction of the parasite loads in infected tissues can
exert positive eﬀects in the clinical evolution of
Chagas disease by reducing the associated inﬂamma-
toryprocesses. In order to further characterize the role
of parasite clearance time induced by diﬀerent
treatments in mice infected with a resistant T. cruzi
VL-10 strain and the outcome of these treatments in
the development of the acute and chronic phases of
experimental Chagas disease, we used the blood and
tissue qPCR to determine the dynamic relationship
between the eﬃcacy of the treatment with posacona-
zole, fexinidazole and benznidazole and the heart
lesion/serum inﬂammatory mediators in experimen-
tal hosts.
MATERIALS AND METHODS
Animal model and parasite strain
Female Swiss mice from the Animal Facility at
Federal University of Ouro Preto (UFOP) were used
in this study. Animals were fed with commercial
food, and water was available ad libitum. Swiss mice
(18–22 g) were inoculated intraperitoneally with
5·0×103 bloodstream trypomastigotes of the VL-10
T. cruzi strain, DTU II, which is resistant to the
benznidazole-treatment (Filardi and Brener, 1987).
Study drugs
Benznidazole: N-Benzyl-2-(2-nitro-1H-imidazol-
1-yl) acetamide (produced by LAFEPE, Brazil),
was administered orally in a water suspension with
0·5% w/v methyl cellulose; fexinidazole: 1-Methyl-2-
{[4-(methylsulfanyl)phenoxy]methyl}-5-nitro-1H-
imidazole, was administrated orally in suspension
containing methyl cellulose 0·5% w/v, with 5% v/v of
polysorbate 80 (Tween 80) and posaconazole: 4-{4-
[4-(4-{[(5R)-5-(2,4-diﬂuorophenyl)-5-(1H-1,2,4-
triazol-1-ylmethyl)oxolan-3-methyl]methoxy}phenyl)
piperazin-1-yl]phenyl}-1-[(2S,3S)-2-hydroxypentan-
3-yl]-4,5-dihydro-1H-1,2,4-triazol-5-one; Noxaﬁl®,
Schering-Plough) was diluted in ultrapure water and
administered orally.
Determination of treatment eﬃcacy by parasite
quantiﬁcation
Theﬁrst set of experimentswas designed todetermine
the kinetics of the parasite clearance induced by
benznidazole, fexinidazole and posaconazole in mice
infected with VL-10 strain. Groups of 30 infected
mice were treated with the diﬀerent compounds. The
drugs were administered at the time of parasitaemia
detection, which occurred at day 10 post-inoculation,
for 20 consecutive days at the doses determined in
previous studies. Benznidazole was administered
at a dose of 100mg kg−1 day−1 (Filardi and Brener,
1987), fexinidazole at a dose of 300mg kg−1 day−1
(Bahia et al. 2012) and posaconazole at a dose of
20mg kg−1 day−1 in two daily doses (Molina et al.
2000).Agroupof 30 animals infectedwith theparasite
but receivingno treatment and30healthymice treated
with the diﬀerent compounds were used as controls.
The kinetics of parasite clearance was investigated
in peripheral blood and in cardiac muscle tissue
samples. For blood evaluation, animals were bled at
10, 12, 14, 16, 20, 30, 40, 50, 60 and 120 days of
infection (di) and parasite quantiﬁcation was per-
formed by microscopic fresh blood examination
(FBE) and qPCR assays. For parasite tissue quantiﬁ-
cation, groups of 6 animals were euthanized at 10, 16,
30, 60 and 120 di and parasite quantiﬁcation was
performed in 30mg of heart muscle tissue by qPCR.
For FBE, the animals were bled from the tail vein,
5 μL of collected blood were used to estimate the
number of parasites as described by Brener (1962).
For the qPCR assay, animals were bled from the
orbital venous sinus and 200 μL of collected blood
was mixed with 35 μL of sodium citrate solution at
129mM (DOLES, BR) and used forDNA extraction.
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DNA extraction was performed using the Wizard®
GenomicDNAPuriﬁcationKit (Promega)with some
modiﬁcations (Caldas et al. 2012). Assays of qPCR
were performed using the SYBR Green system
(Roche Applied Science, Mannheim, Germany)
according to the manufacturer’s instructions and
using the primers TCZ-F 5′-GCTCTTGCCC
ACAMGGGTGC-3′, where M=A or C and
TCZ R 5′-CCAAGCAGCGGATAGTTCAGG-3′
(Invitrogen™) for T. cruzi DNA ampliﬁcation
(Cummings and Tarleton, 2003). The internal
control (corresponding to a segment of the murine
TNF-α gene) was ampliﬁed using the primers
TNF-5241 5′-TCCCTCTCATCAGTTCTATG
GCCCA-3′ and TNF-5411 5′-CAGCAAGCA
TCTATGCACTTAGACCCC-3′ (Invitrogen™)
(Cummings andTarleton, 2003). Cycles of ampliﬁca-
tion were carried out in StepOnePlus real-time PCR
System, Applied Biosystems. The cycles consisted
of an initial denaturation hold of 10min at 95 °C
followed by 40 cycles of 15 s at 94 °C and 1min at
64·3 °C with ﬂuorescence acquisition. Ampliﬁcation
was immediately followed by a melt programme
with an initial denaturation for 15 s at 95 °C, cooling
to 60 °C for 1min and then a stepwise temperature
increase of 0·3 °C s−1 from 60 to 95 °C. All samples
were analysed in duplicate and the mean quantiﬁca-
tion values for T. cruzi DNA were normalized by
the data obtained with the murine-speciﬁc (TNF-α)
primers. Standard curves were performed using
5-fold serial dilutions of an initial suspension of
5×106 parasites/0·1 mL of mice blood (for qPCR in
blood) or 106 parasites/30 mg of heart muscle tissue
(for qPCR in tissue). Negative samples and reagent
controls were processed in parallel in each assay, and
all experiments were conducted under controlled
conditions.
Myocardial tissue assessment
For morphometric analysis, mice were euthanized
at 10, 30 and 120 di (6 animals/group/day) and heart
tissues ﬁxed with 10% formalin and embedded
in paraﬃn. Blocks were cut into 4 μm sections and
stained by hematoxylin-eosin (H&E) for inﬂamma-
tion assessment (10, 30 and 120 di) or Masson’s
trichromic for ﬁbrosis quantitative evaluation
(120 di). Twenty ﬁelds from H&E or Masson’s
trichromic slides were randomly chosen at 40×
magniﬁcation for a total of 74931 μm2 analysed
myocardium area. Images were captured using a
Leica DM 5000 B microcamera (Leica Application
Suite, model 2·4·0R1) and processed by the software
Leica Qwin V3 image analyser.
CCL2, CCL5 and NO levels
For immunoassays, animals were bled at 10, 30 and
120 di. Plasma levels of CCL2 and CCL5 were
measured by ELISA using commercially available
antibodies and according to the procedures supplied
by themanufacturer (DuoSet® ELISADevelopment
System, RandD Systems®, Minneapolis, MN sys-
tems). ELISA measurements for a given experiment
were conducted in duplicate in the same plate.
Results were expressed as pgmL−1 and the detection
limits of the ELISA assays were in the range of
250–3·9 pgmL−1 for CCL2 and 2000–31·25 pgmL−1
for CCL5.
Nitric oxide production was evaluated by nitrite
measurement, and its stable degradation product by
the Griess reaction. Total nitrite/nitrate levels were
determined by the conversion of nitrate to nitrite
using nitrate reductase in the presence of reduced
nicotinamide adenine dinucleotide phosphate and
ﬂavinadenine dinucleotide. After centrifugation each
plasma sample (50 μL) was added to 50 μL of the
Griess solution (1% sulfanilamide, 0·1% N-(1-
Naphthyl) ethylenediamine dihydrochloride, 2·5%
H3PO4). Absorbance was measured at 550 nm in the
microplate ELISA reader (model 680, BioRad).
Nitrite concentrations were determined by using a
standard sodium nitrite curve from 125 to 1 μM.
Statistical analysis
Data were expressed as mean±S.D. Statistical diﬀer-
ence for parasitological data among groups of mice at
diﬀerent days, as well as cytokine levels and intensity
of cardiac inﬂammation and ﬁbrosis, were deter-
mined by the non-parametric Kruskal–Wallis test.
Values of P<0·05 were considered signiﬁcant.
RESULTS
In the ﬁrst set of experiments, we evaluated the
clearance time of parasites induced by fexinidazole,
posaconazole and benznidazole treatments in Swiss
mice infected with T. cruzi stock that was resistant
to benznidazole. Infection of Swiss mice with the
VL-10 strain resulted in an acute parasitaemic phase
easily detectable by FBE from 10 to 30 di, peaking at
16 di with average levels of 8·2×105 parasites/0·1 mL
of blood. Similar results were observed in the blood
and cardiac tissue using qPCR assay, since a higher
parasite load was detected in blood (5·6×105 para-
sites/0·1 mL) and heart tissue (2·6×104 parasites/
30mg of tissue) samples at 16 di. However, in the
chronic phase, the parasitism was only detected by
qPCR assay, being higher in the cardiac tissue than in
the blood tissue (Table 1).
Our results showed that fexinidazole and posaco-
nazole induced a faster parasitaemia clearance than
benznidazole (parasites were not detected at the 6th
day of treatment, 16 di, by FBE) (Fig. 1a and
Table 1). This result was conﬁrmed by qPCR assay,
since the parasitaemia detected was several times
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lower in blood samples of animals treated with
fexinidazole (121 parasites/0·1 mL) and posaconazole
(17 parasites/0·1 mL) than detected in samples
collected from benznidazole-treated animals
(1·09×104 parasites/0·1 mL). At this time, all mice
treated with benznidazole had positive parasitaemia
in the qPCR assay, while the same results were
detected in 33% of samples collected in posaconazole
and in 50% of fexinidazole-treated animals (Fig. 1b).
Additionally, at the last day of treatment (30 di), the
qPCR assay had negative results in all blood samples
of fexinidazole- and posaconazole-treated mice
(Fig. 1b). The same result was found in only 50% of
animals treated with benznidazole, and the positive
results had lower levels (3 parasites/0·1 mL of blood)
than the infected and non-treated group (1·49×105
parasites/0·1 mL blood) (Table 1).
As the clearance of parasites in the peripheral
circulation may not always be correlated with the
clearance in the tissue, we also evaluated the cardiac
parasitism of treated mice. The treatments induced a
reduction of cardiac parasite load (119–160 parasites/
30mg of heart tissue) at the 6th day of treatment,
while in the samples of infected and non-treated
Table 1. Parasite load in benznidazole-, posaconazole- and fexinidazole-treated mice infected with VL-10
Trypanosoma cruzi strain1,2
Treatments2 Days post infection
(Parasites mean±S.D.)3
FBE4 Blood-PCR5 Heart-PCR5
Non-treated 10 26·667±18·09 17·292±18·75 9·596±10·27
16 827·333±532·32 561·038±237·54 26·114±15·72
30 113·000±169·71 149·349±130·11 7·753±7·33
60 0 0·159±0·18 2·609±1·83
120 0 0·175±0·15 0·925±0·49
Benznidazole (100mg kg−1 day−1) 10 20·000±14·53 26·573±20·02 7·200 ±15·33
16 3·333±3·93 10·912±8·27 0·160±0·14
30 0 0·003± 0·005 0·006±0·014
60 2·000±2·190 9·532 ±10·75 0·059±0·03
120 0 0·614±0·40 0·116±0·08
Posaconazole (40mg −1kg day−1) 10 14·666±10·93 18·384±13·69 10·449±6·12
16 0 0·017±0·03 0·123±0·13
30 0 0 0·029±0·06
60 1·333±2·06 19·669±12·56 2·306±3·34
120 0 1·314±1·17 0·694±0·88
Fexinidazole (300mg kg−1 day−1) 10 16·000±11·86 23·666±23·46 12·022±6·32
16 0 0·121±0·26 0·119±0·12
30 0 0 0
60 0 0 0
120 0 0 0
1 Swiss female (n= 6) weight 18 to 22 g inoculated with 5×103 trypomastigotes.
2 Treatment was initiated at 10 day after inoculation followed by 20 days and it was administered per oral route.
3 Data refer to the number of parasites in 0·1 mL of blood or 30mg of heart tissues ×103.
4 FBE – fresh blood examination.
5 Real-time PCR in blood (Blood-PCR) and in heart tissues (Heart-PCR).
Fig. 1. Trypanosoma cruzi clearance curves. Parasite clearance time in mice infected with VL-10 benznidazole-resistant
T. cruzi strain during (10 to 30 di) and after (40 to 120 di) benznidazole, posaconazole and fexinidazole treatment. (a)
Results determined by fresh blood examination; (b) real-time PCR in blood and (c) in heart tissues of treated mice.
n= 6; di, days of infection.
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mice, there were 2·6×104 parasites/30mg of heart
tissue (Table 1). At this time, parasites were detected
in 50% of the tissue samples collected from posaco-
nazole-treated animals and in all of the samples
of fexinidazole- and benznidazole-treated mice,
suggesting a quick response of posaconazole in the
management of tissue parasitism in low or ‘con-
trolled’ levels during a therapeutic regimen (Fig. 1c),
since during the treatment, multiplication of the
parasite was low in cardiac tissue, as compared with
that observed before treatment, or between non-
treated animals (Table 1). However, at the last day
of treatment, the qPCR had negative results in all
fexinidazole-treated animals, while negative results
were detected in only 50% of those treated with
benznidazole and posaconazole (Fig. 1c). Interest-
ingly, our results with posaconazole showed that the
parasite clearance was ﬁrst detected in peripheral
blood (Table 1 and Fig. 1a–c). For these mice, at the
last day of the treatment, the qPCR had negative
results in all blood samples and in 50% of the tissue
samples. However, after the end of the treatment, an
increase of parasitism was detected in both peripheral
blood and heart tissue samples of animals treatedwith
posaconazole and benznidazole, reaching similar or
higher levels than those detected in samples obtained
in infected and non-treated animals (Table 1). The
parasitaemia reactivation was detected faster in
benznidazole-treated animals than in mice treated
with posaconazole (Fig. 1a and b). Diﬀerent data
were detected in fexinidazole-treated animals, since
after the 6th day of treatment until the end of
evaluation (at 120 di), the qPCR had negative results
(Table 1 and Fig. 1c). Interestingly, the qPCR assay
carried out after the end of the treatment with
samples of mice treated with benznidazole or
posaconazole showed a higher parasitism level in
blood than in the cardiac tissue, this result being
opposite to that found in the infected and untreated
animals (Table 1).
In all experiments, the evaluated compounds were
well tolerated by animals and mortality was not
detected among treated mice. Additionally, no
diﬀerences in weight gain were found among treated
and non-infected animals during all of the evaluated
period (data not shown).
In order to assess the eﬀectiveness of these diﬀerent
treatments in reducing or preventing the develop-
ment of myocardial lesions in infected mice, a
quantitative analysis of inﬂammation in the heart
tissue was performed before treatment (10 di), at
the acute (30 di) and chronic (120 di) phases of the
infection. Treatments were able to reduce the
number of inﬂammatory cells at the acute phase of
experimental T. cruzi infection, as observed by a
signiﬁcant increase of inﬂammatory inﬁltrates in the
hearts of the infected non-treated animals. However,
mice treated with benznidazole presented a higher
number of inﬂammatory cells than the healthy mice
(Fig. 2a). In contrast, fexinidazole and posaconazole
treatments prevent heart inﬂammation, as illustrated
by similar levels of inﬂammatory intensity between
treated and healthy animals (Fig. 2a).
The increased parasite loads during the chronic
phase of the infection are in line with the increased
amount of inﬂammatory cells in the cardiac tissue of
benznidazole- and posaconazole-treated mice. At this
time, mice treated with benznidazole and posacona-
zole had a higher number of inﬂammatory cells than
did the healthy mice (Figs 3a and 4). Interestingly,
the comparison of the number of inﬂammatory cells
in the heart tissue of animals treated with diﬀerent
compounds allowed ordering of the eﬀects of
the drugs as follows: (benznidazole <posaconazole
<fexinidazole). The means and standard deviations,
including the values of controls, were: benznidazole =
286·1±10·8 cells/74931 μM2; posaconazole = 269·1±
17·7 cells/74931 μM2; fexinidazole = 221·4±13·3
cells/74931 μM2 and healthy animals = 217·5±23·4
cells/74931 μM2. Moreover, analysis of the ﬁbrotic
area in the hearts of the treated mice showed that all
treatments were eﬃcient in reducing ﬁbrosis in the
chronic phase of experimental infection. Interest-
ingly, among animals treated with posaconazole and
fexinidazole, a similar heart ﬁbrosis intensity with
healthy mice was detected, but signiﬁcant diﬀerences
were observed when the heart ﬁbrotic area from
healthy and benznidazole-treated mice were com-
pared (Figs 3b and 4).
We also evaluated the CCL2, CCL5 and NO
levels in the plasma of the treated and control animals
in order to compare the eﬃcacy of the treatments
on the leucocyte chemotractant mediators and NO
proﬁles. The proﬁle of chemokines CCL5 (Fig. 2b)
and CCL2 (Fig. 2c) detected in the plasma of infected
and non-treated animals was correlated with the
parasite load, showing an increase in the early
phase of the infection (10 di) peaking at 30 di with
plasma levels*3-fold (CCL5) and*6-fold (CCL2);
higher compared with healthy mice. The level of
these chemokines was reduced during the chronic
phase of infection, but remained signiﬁcantly higher
than those detected in the plasma of healthy mice
(Fig. 3c and d). A diﬀerent pattern was observed in
animals treated with the evaluated compounds, and
correlated with their anti-T. cruzi activity. At the end
of the treatments, the chemokine levels among the
treated animals were similar to those detected in
healthy animals (Fig. 2b and c). However, at the
chronic phase, the chemokine pattern presented
particularities according to the compounds used:
(i) similar between infected untreated and benznida-
zole-treated mice; (ii) posaconazole-treated mice
had similar CCL2 and smaller CCL5 plasma levels
(P<0·05) than the infected mice; and (iii) fexinida-
zole-treated mice had plasma chemokine levels
indistinguishable from those of healthy animals
(Fig. 3c and d).
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Levels of NO were also measured in both phases
of infection, as shown in Figs 2d and 3e. At 30 di,
plasma concentrations of NO reached *3·3-fold
higher than those observed for healthy mice
(Fig. 2d). Interestingly, when the parasitism was
controlled, there was a decrease in NO, reaching
levels similar to those of healthy animals at 120 di,
and the treated ones, who always had NO levels
similar to healthy mice (Fig. 3e).
To conﬁrm the inﬂuence of evaluated compounds
on CCL2, CCL5 and NO levels, healthy animals
were treated using the same therapeutic regime,
and chemokines and NO dosages were performed
after treatment. Our results showed no signiﬁcant
diﬀerence between the chemokines and NO levels
detected in the plasma sample of healthy animals,
treated or not, showing that drugs used, by them-
selves, do not interfere in these plasma inﬂammatory
mediators.
DISCUSSION
Some studies consider that despite their inability to
eradicate the parasite, the drug-induced reduction of
the parasite loads in infected tissues has positive
eﬀects on the clinical evolution of the T. cruzi
infection by reducing the severity of the associated
inﬂammatory processes (Andrade et al. 1991;
Tarleton et al. 1994; Hardison et al. 2006; Caldas
et al. 2008).
To characterize the role of parasite clearance time
induced by diﬀerent treatments and their outcome
on Chagas disease, we used qPCR and deﬁned
the dynamic relationship between the eﬃcacy of the
treatments and the heart tissue damage during the
acute and chronic stages of the infection in mice.
In the acute infection, the treatment eﬃcacy to induce
parasitic clearance and disease severity showed
absolute correlation. Furthermore, drug clearance
of parasites induced by the fexinidazole treatment
resulted in the disappearance of inﬂammatory lesions
and the resolution of the disease. Previous studies
failed to show a correlation between parasitic burden,
disease progression and severity (Ãnez et al. 1999;
Tarleton and Zhang, 1999; Caldas et al. 2008).
Here, the comparisons of blood and tissue parasite
loads along the course of infection indicate that all
treatments initiated in the acute phase were able
to induce a global decrease of parasite loads in
both peripheral blood and cardiac tissue, but with
Fig. 2. Inﬂammatory outcome from treated mice during acute phase of Trypanosoma cruzi infection. Mice were infected
with 5000 trypomastigotes of VL-10 strain and treated with benznidazole (Bz), posaconazole (Pz) or fexinidazole (Fex).
Animals were euthanized before treatment (10 days of infection) and after treatment (30 days of infection). For controls,
infected and non-treated (IC) and non-infected (NIC) groups were evaluated. (a) Myocardial inﬂammatory cell count in
heart muscle of mice. (b) CCL5, (c) CCL2 and (d) NO levels in plasma sample compared with control groups before
and after treatment. # denotes signiﬁcant diﬀerences in relation to non-infected mice (P<0·05). * denotes signiﬁcant
diﬀerences in relation to infected and non-treated (P<0·05).
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diﬀerent eﬃcacies. Posaconazole and fexinidazole
treatments induced a faster parasite clearance in
relation to benznidazole. Among the posaconazole-
treatedmice, thebloodparasite clearancewas detected
upon both FBE and qPCR. However, the parasites
were still detected in 50% of tissue samples from the
heart. These results indicate that the determination of
parasite DNA in blood does not reﬂect the actual
parasitic load in cardiac tissue when performed
immediately after the end of treatment and it is not
suﬃcient at this time to assess the eﬀect of treatment.
As an overall analysis, our results indicated that
evaluated compounds presented potent activity
against the VL-10T. cruzi strain, but with individual
particularities in their potency. The potent anti-
T. cruzi activity of fexinidazole could be related to its
pharmacokinetic properties. Fexinidazole is rapidly
oxidized in vivo in two more therapeutically relevant
species, sulphoxide and sulphone metabolites.
A high and prolonged systemic bioavailability of
these metabolites is achieved a few hours after drug
administration (Sokolova et al. 2010). Although
both metabolites present anti-T. cruzi activity
(Bahia et al. 2014), fexinidazole sulphoxide is
extensively converted to sulphone, the ﬁnal metab-
olite to appear in the blood. Fexinidazole sulphone
presents a better pharmacokinetic proﬁle, as half-life
and plasma concentrations, superior to sulphoxide
metabolite and benznidazole (Workman et al. 1979;
Bahia et al. 2014) and is the species most likely
associated with eﬃcacy following administration of
fexinidazole.
Fig. 3. The outcome of treatment on the development of the chronic phase of experimental Chagas disease. Mice were
inoculated with 5000 trypomastigotes of VL-10 strain and treated with benznidazole (Bz), posaconazole (Pz) or
fexinidazole (Fex) and euthanized at 90 days after treatment (120 days after inoculation). For controls, infected and non-
treated (IC) and non-infected (NIC) groups were evaluated. (a) Myocardial inﬂammatory cell count in heart muscle of
mice. (b) Fibrosis area in heart muscle of mice. (c) CCL5, (d) CCL2 and (e) NO levels in plasma sample of mice
compared with control groups, 90 days after treatment. # denotes signiﬁcant diﬀerences in relation to non-infected mice
(P<0·05). * denotes signiﬁcant diﬀerences in relation to infected and non-treated (P<0·05).
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Our data demonstrate that early treatment prevents
severe disease progression, due to the control of
parasitic replication and its consequent immuno-
pathological implications. Probably, these events
induced a balance between the clearance of the
parasites and the prevention of the immune-mediated
pathology. The degree of regression relates to the
successful treatment with cured mice showing the
most pronounced reversal of the pathological signs.
In agreement with our data, several authors have
shown that even in cases of treatment failure, there
was a reduction in the parasitic load as well as in the
cardiac lesions, events followed by a slow progression
of chronic cardiac injury (Andrade et al. 1991; Garcia
et al. 2005; Caldas et al. 2008; Diniz et al. 2010;
Santos et al. 2012).
According to Andrade et al. (1991), the presence
of the parasite and the inﬂammatory process underlie
the pathological evolution of chronic Chagas disease.
In the present work, chemokines and NO were
measured in the plasma samples at the same time
that parasitic load and cardiac tissue lesion evalua-
tions were performed. The increased parasite load is
in line with the increased amount of CCL2 and
CCL5 observed in the plasma of these animals as
compared with healthy or cured mice. Interestingly,
at the chronic phase, only benznidazole-treated
animals presented a signiﬁcantly higher ﬁbrotic area
in the cardiac tissue in comparison with healthy
animals, as well as higher levels of CCL2 and CCL5
chemokines. However, the intensity of heart ﬁbrosis
was higher in infected and untreated animals,
demonstrating the beneﬁcial eﬀect of the reduction
of the tissue parasitism induced by diﬀerent treat-
ments in the disease outcome, even in the absence of
parasitological cure. In agreement, a study involving
chemokine expression in the heart of chronically
T. cruzi-infected beagle dogs with the cardiac form
also showed increased mRNA expressions of
CXCR3, CCL4 and CCL5 as compared with those
in the indeterminate form (Guedes et al. 2004).
In the present study, all evaluated compounds
induced a strong reduction in the parasite load,
displaying their potent anti-T. cruzi activity.
However, a relapse of parasitaemia was detected in
benznidazole- and posaconazole-treated mice show-
ing that these compounds were not eﬀective in
inducing parasitological cure in mice infected with
VL-10 strain. These results were in line with Filardi
and Brener (1987) who showed the full resistance of
the VL-10 strain to benznidazole. Molina et al.
(2000) have reported the eﬃcacy of posaconazole in
curing mice infected with benznidazole-resistant
T. cruzi strain in a long-term treatment (28 days,
7 days rest and another 15 days). However, a phase II
clinical trial to investigate the eﬃcacy and safety of
posaconazole in Spain (http://clinicaltrials.gov/ct2/
show/NCT01162967?term=posaconazole) resulted
in good safety, but unfortunately, this compound
had little to no sustained eﬃcacy in treating patients
in the chronic phase of Chagas disease as a single
medication (Israel Molina, International Congress of
Tropical Medicine http://ictmm2012.ioc.ﬁocruz.br/
program_25_sept.html). These results highlight
the need to investigate alternative dosing regimens
and possible combination therapies to improve
treatment eﬃcacy. This idea is in line with others;
Pinazo et al. (2010) described a successful resolution
of a T. cruzi infection (a case of chronic Chagas
disease and systemic lupus erythematosus) following
treatment with posaconazole (400mg for 12 h during
90 days). Previous treatment of the same patient
with benznidazole induced a reduction, but not a
complete elimination of the parasite. These results
indicate that more prolonged therapeutic regimens
may be needed to improve Chagas disease treatment
Fig. 4. Treatment reduces chronic Chagas disease-associated inﬂammatory and ﬁbrotic pathology. Analysis of
histological sections of hearts from mice infected with VL-10 strain of Trypanosoma cruzi, 40× magniﬁcation. (A–E)
Hematoxylin-eosin staining for inﬂammation assessment and (F–J) Masson’s trichromic for ﬁbrosis assessment. (A and
F) Myocardial sections from healthy mice, (B and G) from infected control non-treated mice, (C and H) from
benznidazole-treated mice, (D and I) from posaconazole-treated and (E and J) from fexinidazole-treated mice at 120
days of infection. # denotes signiﬁcant diﬀerences in relation to non-infected mice (P<0·05). * denotes signiﬁcant
diﬀerences in relation to infected and non-treated mice (P<0·05).
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eﬃcacy with azoles derivatives. Additionally, the
diﬀerent mechanisms of action and pharmacological
characteristics of benznidazole, posaconazole and
fexinidazole (Wilkinson and Kelly, 2009; Urbina,
2010; Bahia et al. 2012) might also contribute to
explaining the diversiﬁed cure rate in VL-10 infected
mice. This idea is corroborated by the observations
of Guedes et al. (2004) showing that diﬀerent
therapeutic strategies using benznidazole (60-day
treatment) and albaconazole (90-day treatment) in-
duced a deﬁnitive cure in dogs infected with T. cruzi
Y strain, while the administration of albaconazole for
60 days was able to cure only 25% (1 of 4) of the
animals. In this scenario, the individualized therapy
schemes, considering both the drug concentration
and the time of treatment, might be important for
therapeutic success.
Finally, the most important observations of this
study were related to the severity of the cardiac
lesions in both the acute and chronic phases of the
infection and the drug-induced parasitaemia clear-
ance time. These observations suggest that the
prevention of T. cruzi infection progression in
Chagas disease severity might be achieved through
chemotherapeutic strategies that enhance parasite
clearance and reduce parasite load in a permanent
way, thereby contributing to a better balance in the
host-parasite relationship.
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